Last updated: August 20, 2026
Zosyn in plastic container is Pfizer’s premixed intravenous formulation of piperacillin and tazobactam, supplied in the GALAXY container. The product remains clinically relevant in hospital treatment of serious bacterial infections, but its commercial position is mature and exposed to generic piperacillin/tazobactam competition. Pfizer does not report Zosyn or the GALAXY presentation as a separate revenue line, so product-specific sales and profitability cannot be calculated from public financial filings. The principal commercial value is in hospital supply reliability, premixed convenience and formulary continuity rather than exclusivity.
What is Zosyn in plastic container?
Zosyn in plastic container is a ready-to-use intravenous solution containing piperacillin sodium and tazobactam sodium. The product is supplied in a flexible GALAXY container and is administered after removal from the overwrap and inspection of the solution.
The product’s FDA-approved indications include moderate-to-severe infections caused by susceptible organisms, including:
- Intra-abdominal infections
- Nosocomial pneumonia
- Skin and skin-structure infections
- Female pelvic infections
- Community-acquired pneumonia in adults
The combination pairs an extended-spectrum penicillin with a beta-lactamase inhibitor. Its hospital use is concentrated in empiric treatment, where broad coverage is needed before final microbiology results are available. FDA labeling identifies dosage strengths based on the piperacillin component, including 3.375 grams and 4.5 grams per dose, with dosing adjusted for renal impairment and the clinical indication (FDA, 2024).
What does the plastic container change?
The GALAXY container is a delivery and packaging format, not a different active pharmaceutical ingredient. Its commercial attributes include:
- Reduced pharmacy compounding requirements
- Lower preparation time
- Lower exposure to compounding and labeling errors
- Compatibility with hospital inventory workflows
- Premixed availability for intermittent and extended infusion protocols
The container can support a price premium over some conventional vial presentations, but that premium is limited by generic premixed products and hospital purchasing pressure. Procurement decisions often compare total treatment cost, pharmacy labor, storage, waste, infusion compatibility and supply continuity rather than unit price alone.
What is the FDA regulatory status of Zosyn in plastic container?
Zosyn is approved under FDA New Drug Application No. 050684. Pfizer is the current reference-product sponsor following its acquisition of Hospira in 2015. Hospira had acquired the relevant injectable-product portfolio from other manufacturers before Pfizer completed the transaction.
The product is regulated as a prescription injectable antibacterial drug. It is not a biologic and does not face biosimilar competition. Generic competitors enter through abbreviated new drug applications, or ANDAs, rather than the biosimilar pathway.
The principal regulatory risks are operational:
- Manufacturing-site compliance
- Sterility assurance
- Container-closure integrity
- Stability and particulate control
- Drug shortages affecting piperacillin/tazobactam supply
- Changes in approved container configuration or labeling
For hospital buyers, FDA approval of the active ingredient does not eliminate the need to assess presentation-specific factors. The premixed bag must meet requirements for sterility, strength, stability, storage and administration compatibility.
What patents protect Zosyn in plastic container?
The original compound and combination patent estate is no longer the primary barrier to generic competition. Piperacillin/tazobactam has been marketed for decades, and the core exclusivity period expired long before the current mature-market phase.
The main protection now resides in manufacturing know-how, validated sterile filling, supply-chain reliability and customer contracts. Those barriers can delay or complicate supply substitution but generally do not create durable patent exclusivity.
Are active Orange Book patents listed for Zosyn?
The FDA Orange Book should be reviewed for the current listing status of NDA 050684 and each approved presentation. Publicly available product information does not support treating Zosyn in plastic container as a product with a meaningful remaining core patent term. Any patent-listed presentation, formulation or method-of-use rights would need to be evaluated by specific patent number, expiration date and statutory status in the current Orange Book.
The commercial conclusion is clear: Zosyn’s market position is not based on an unexpired composition-of-matter patent. A generic manufacturer can generally compete on the same active ingredients if it satisfies the ANDA requirements for pharmaceutical equivalence, bioequivalence where applicable, manufacturing quality and injectable-product controls.
When did Zosyn lose exclusivity?
Zosyn lost practical market exclusivity years ago as generic piperacillin/tazobactam products entered hospital markets. The product is now in the mature injectable-antibiotic category.
A simplified exclusivity timeline is:
| Period |
Commercial event |
Market impact |
| 1990s |
Original piperacillin/tazobactam approval and hospital launch |
Establishment of broad-spectrum beta-lactam franchise |
| Late 1990s to early 2000s |
Expansion of hospital use and premixed delivery formats |
Increased pharmacy and inpatient adoption |
| 2000s onward |
Generic piperacillin/tazobactam availability |
Price pressure and formulary substitution |
| 2015 |
Pfizer acquisition of Hospira |
Pfizer assumes the injectable portfolio and supply infrastructure |
| Current market |
Mature branded and generic competition |
Volume depends on hospital contracts, supply and shortages |
The product can still generate sales after patent expiry because hospital switching is constrained by supply qualification, formulary protocols, clinician familiarity and purchasing agreements. Those factors preserve residual branded demand but do not restore exclusivity.
How many patents cover Zosyn in plastic container?
No reliable commercial analysis should state a single patent count without fixing the jurisdiction, patent family, listed-patent database and cutoff date. Patent counts can include expired composition patents, abandoned applications, continuations, formulation claims, process patents and foreign equivalents.
For the U.S. market, the relevant conclusion is that any remaining patent count is less important than whether a live, enforceable patent blocks an ANDA or a particular premixed presentation. The mature status of piperacillin/tazobactam indicates that generic entry is governed primarily by regulatory and manufacturing requirements, not by a central blocking patent.
What formulation patents protect the premixed bag?
The GALAXY container may involve proprietary formulation and packaging know-how relating to:
- Concentration and pH control
- Stability of piperacillin and tazobactam in solution
- Container materials
- Oxygen and moisture exposure
- Storage temperature
- Overwrap design
- Sterile filling and terminal processing
- Compatibility with intravenous administration
These technical elements can be protected by patents, trade secrets or process controls. They do not automatically prevent an ANDA applicant from developing a different formulation or container that meets FDA requirements.
Which companies challenge Zosyn in the generic market?
Generic competition comes from manufacturers of piperacillin/tazobactam injection and premixed or pharmacy-ready presentations. The competitive set can change because FDA approvals, discontinued products and shortage-driven supply fluctuate.
Relevant competitors include manufacturers such as:
- Sandoz
- Hikma Pharmaceuticals
- Aurobindo Pharma
- Eugia and related injectable operations
- Fresenius Kabi
- Baxter, where applicable by presentation or distribution channel
- Other ANDA holders and contract manufacturers
The exact competitive landscape depends on whether the comparison is limited to ready-to-use flexible bags, conventional vials, specific strengths or particular hospital contracting channels. A vial product is a competitive substitute but not necessarily a direct presentation equivalent to Zosyn in a GALAXY container.
What generic entry risks exist for Zosyn?
Generic entry risk is high because the active ingredient combination is old, clinically established and widely used. The remaining commercial defenses are weaker than those available to a newly launched branded injectable.
Why hospital conversion is not immediate
Hospitals may delay conversion because of:
- Contract terms
- Pharmacy validation requirements
- EHR and order-set changes
- Shortage concerns
- Differences in bag size or dose availability
- Infusion-pump compatibility
- Stability and beyond-use requirements
- Manufacturer reliability
- Recall history
- Distributor allocation limits
These factors reduce the speed of substitution but do not prevent it. When a generic competitor offers equivalent supply at a lower acquisition cost, large integrated delivery networks and group purchasing organizations can move substantial volume.
What would trigger a generic launch?
A generic manufacturer is most likely to gain share when it can provide:
- FDA-approved equivalent strength and route
- Reliable sterile manufacturing capacity
- Comparable storage and administration requirements
- Competitive contract pricing
- Adequate distribution through hospital wholesalers
- A demonstrated ability to maintain supply during shortages
For injectable antibiotics, capacity and reliability can matter as much as nominal price. A low-priced supplier that cannot maintain production may fail to displace a branded product with stronger availability.
What patent litigation and Paragraph IV activity affect Zosyn?
Zosyn is not primarily an active patent-litigation asset. The product’s market maturity and generic availability reduce the likelihood that a new Paragraph IV dispute would materially change its commercial trajectory.
Paragraph IV litigation is relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable or not infringed. For a mature product such as piperacillin/tazobactam, any such dispute would likely concern a specific formulation, dosage presentation or method-of-use patent rather than the basic active ingredients.
A litigation review should distinguish:
- Patent cases involving the original piperacillin/tazobactam combination
- Cases involving premixed container technology
- ANDA suits against a particular generic applicant
- Patent settlements that delay launch
- Product-liability or manufacturing cases unrelated to market exclusivity
No current litigation record should be treated as a material barrier to generic competition without a live patent, an asserted claim and a court or settlement outcome that affects launch timing.
How does Zosyn compare with competing hospital antibiotics?
Zosyn competes across several hospital antibiotic classes rather than against a single product. Its main substitutes include cefepime, meropenem, ertapenem, ceftriaxone-based regimens and other beta-lactam/beta-lactamase inhibitor combinations.
| Product or class |
Main competitive factor |
Impact on Zosyn |
| Cefepime |
Broad gram-negative coverage and lower acquisition cost in some settings |
Substitution in selected empiric regimens |
| Meropenem |
Stronger position for resistant organisms |
Used when ESBL or severe resistance is suspected |
| Ampicillin/sulbactam |
Narrower or different coverage profile |
Alternative for selected infections |
| Ceftriaxone-based therapy |
Lower-cost community and inpatient use |
Reduces use where antipseudomonal coverage is unnecessary |
| Newer beta-lactam combinations |
Resistance-focused treatment |
Captures complex or resistant-infection cases |
Antimicrobial stewardship also limits broad-spectrum use. Hospitals may reserve Zosyn for patients with suspected Pseudomonas or polymicrobial infection and de-escalate therapy when cultures are available.
What is the financial trajectory for Zosyn in plastic container?
Pfizer does not separately disclose Zosyn revenue, unit volume, gross margin or GALAXY-container sales in its annual reports. The product is included within broader reporting structures for established pharmaceutical products and hospital injectables. Any precise product-level revenue estimate would therefore be model-based rather than reported.
The financial trajectory is best characterized as mature, declining in price and dependent on volume retention:
| Financial driver |
Expected direction |
Commercial effect |
| Average selling price |
Downward |
Generic competition and hospital contracting |
| Branded volume |
Flat to declining |
Formulary substitution and stewardship |
| Premixed presentation demand |
Relatively resilient |
Pharmacy labor and convenience benefits |
| Gross margin |
Under pressure |
Price erosion and manufacturing costs |
| Revenue visibility |
Limited |
No separate Pfizer disclosure |
| Supply-related upside |
Episodic |
Shortages can temporarily support branded demand |
| Long-term growth |
Low |
Mature antibiotic category |
Zosyn can retain revenue despite patent expiry when generic shortages, hospital contracts or supply reliability favor the branded supplier. Such gains are typically temporary and should not be modeled as structural growth.
What is the revenue exposure for Pfizer?
Zosyn is unlikely to be a material driver of Pfizer’s consolidated financial performance compared with its largest innovative medicines and vaccines. Its value is more relevant at the hospital-products and sterile-injectables portfolio level.
The commercial exposure has three dimensions:
- Direct sales of branded piperacillin/tazobactam
- Portfolio leverage through hospital contracts
- Strategic value from manufacturing and distribution infrastructure
Revenue risk is concentrated in price erosion, supply interruptions and loss of institutional contracts. The product does not carry the same patent-cliff exposure as a recently launched specialty medicine because most exclusivity erosion has already occurred.
What manufacturing and intellectual-property barriers remain?
Manufacturing is the main defensible barrier. Sterile injectable production requires validated facilities, environmental controls, aseptic processing, container-closure testing and reliable supply of active pharmaceutical ingredients.
The most important barriers include:
- Limited global sterile manufacturing capacity
- Qualification of flexible plastic containers
- Stability in solution over the labeled shelf life
- Control of particulate contamination
- High cost of facility remediation
- FDA inspection and warning-letter risk
- Supply-chain concentration for active ingredients
- Hospital qualification and vendor onboarding
These barriers can create temporary pricing power during shortages. They do not provide the predictable, long-duration protection associated with an active composition patent.
Is Zosyn in plastic container commercially attractive for licensing?
Licensing appeal is limited for a conventional branded product with mature active ingredients and generic competition. Potential value may exist in:
- Regional distribution rights
- Government and hospital contracts
- Supply agreements
- Contract manufacturing
- Premixed delivery technology
- Shortage-resilient sterile capacity
- Combination products with differentiated administration systems
A license based solely on the Zosyn brand or active ingredients would face weak exclusivity economics. A transaction centered on manufacturing capacity or hospital-channel access would have a stronger commercial rationale.
Key Takeaways
- Zosyn in plastic container is Pfizer’s premixed piperacillin/tazobactam injection in the GALAXY flexible container.
- The product is FDA-approved under NDA 050684 and is a mature hospital antibiotic.
- Core compound exclusivity has expired, and generic competition is established.
- The product has no biosimilar risk because it is a small-molecule injectable, not a biologic.
- The commercial moat is based on supply reliability, premixed convenience, hospital contracts and sterile-manufacturing capability.
- Pfizer does not separately report Zosyn or GALAXY-container revenue.
- Financial performance is likely characterized by declining price, mature or declining branded volume and episodic supply-related demand.
- Patent litigation is not the principal current risk; generic pricing and manufacturing competition are more important.
- A major generic launch could reduce branded volume quickly if the competitor offers equivalent premixed presentations and dependable supply.
FAQs
Does Zosyn in plastic container have remaining market exclusivity?
No meaningful core market exclusivity remains. The product competes in a generic market, although branded sales can persist through hospital contracts and supply advantages.
Is Zosyn in GALAXY container the same drug as piperacillin/tazobactam injection?
Yes. GALAXY is the delivery container and presentation. The active combination is piperacillin sodium and tazobactam sodium.
Can generic manufacturers copy the Zosyn plastic bag?
They can develop an equivalent FDA-approved premixed injectable using their own formulation, container and manufacturing process. They do not need to copy Pfizer’s proprietary design exactly.
Does Zosyn face biosimilar competition?
No. Biosimilar regulation applies to biological products. Zosyn is a small-molecule antibacterial drug and faces ANDA-based generic competition.
What is the most important investment risk for Zosyn?
The main risk is continued price and volume erosion from generic suppliers, compounded by hospital formulary substitution. Manufacturing shortages can temporarily improve branded demand but are not a durable growth strategy.
References
- U.S. Food and Drug Administration. (2024). Zosyn (piperacillin and tazobactam) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Pfizer Inc. (2015). Pfizer completes acquisition of Hospira.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Zosyn NDA 050684.
